Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial
Background Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and internationally led the World Health Organization to declare a Public Health Emergency of International Concern on $ 30^{th} $ January 2020. The clinical manifestations of COVID-19 virus infection include asymptomatic infection, mild upper respiratory symptoms, severe viral pneumonia with respiratory failure, and even death. There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the efficacy and safety of remdesivir in adult patients with severe COVID-19. Methods The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. This is a phase 3, randomized, double-blind, placebo-controlled, multicentre trial. Adults (≥ 18 years) with laboratory-confirmed COVID-19 virus infection, severe pneumonia signs or symptoms, and radiologically confirmed severe pneumonia are randomly assigned in a 2:1 ratio to intravenously administered remdesivir or placebo for 10 days. The primary endpoint is time to clinical improvement (censored at day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six-category ordinal scale of clinical status (1 = discharged; 6 = death) or live discharge from hospital. One interim analysis for efficacy and futility will be conducted once half of the total number of events required has been observed. Discussion This is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan, Hubei Province, China on $ 6^{th} $ February 2020. Trial registration ClinicalTrials.gov: NCT04257656. Registered on 6 February 2020..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Trials - 21(2020), 1 vom: 24. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yeming [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Administrative information |
| Anmerkungen: |
© The Author(s) 2020 |
|---|
| doi: |
10.1186/s13063-020-04352-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2117778941 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2117778941 | ||
| 003 | DE-627 | ||
| 005 | 20240322035559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230504s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-020-04352-9 |2 doi | |
| 035 | |a (DE-627)OLC2117778941 | ||
| 035 | |a (DE-He213)s13063-020-04352-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Wang, Yeming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2020 | ||
| 520 | |a Background Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and internationally led the World Health Organization to declare a Public Health Emergency of International Concern on $ 30^{th} $ January 2020. The clinical manifestations of COVID-19 virus infection include asymptomatic infection, mild upper respiratory symptoms, severe viral pneumonia with respiratory failure, and even death. There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the efficacy and safety of remdesivir in adult patients with severe COVID-19. Methods The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. This is a phase 3, randomized, double-blind, placebo-controlled, multicentre trial. Adults (≥ 18 years) with laboratory-confirmed COVID-19 virus infection, severe pneumonia signs or symptoms, and radiologically confirmed severe pneumonia are randomly assigned in a 2:1 ratio to intravenously administered remdesivir or placebo for 10 days. The primary endpoint is time to clinical improvement (censored at day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six-category ordinal scale of clinical status (1 = discharged; 6 = death) or live discharge from hospital. One interim analysis for efficacy and futility will be conducted once half of the total number of events required has been observed. Discussion This is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan, Hubei Province, China on $ 6^{th} $ February 2020. Trial registration ClinicalTrials.gov: NCT04257656. Registered on 6 February 2020. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a Antiviral | |
| 650 | 4 | |a China | |
| 650 | 4 | |a Administrative information | |
| 700 | 1 | |a Zhou, Fei |4 aut | |
| 700 | 1 | |a Zhang, Dingyu |4 aut | |
| 700 | 1 | |a Zhao, Jianping |4 aut | |
| 700 | 1 | |a Du, Ronghui |4 aut | |
| 700 | 1 | |a Hu, Yi |4 aut | |
| 700 | 1 | |a Cheng, Zhenshun |4 aut | |
| 700 | 1 | |a Gao, Ling |4 aut | |
| 700 | 1 | |a Jin, Yang |4 aut | |
| 700 | 1 | |a Luo, Guangwei |4 aut | |
| 700 | 1 | |a Fu, Shouzhi |4 aut | |
| 700 | 1 | |a Lu, Qiaofa |4 aut | |
| 700 | 1 | |a Du, Guanhua |4 aut | |
| 700 | 1 | |a Wang, Ke |4 aut | |
| 700 | 1 | |a Lu, Yang |4 aut | |
| 700 | 1 | |a Fan, Guohui |4 aut | |
| 700 | 1 | |a Zhang, Yi |4 aut | |
| 700 | 1 | |a Liu, Ying |4 aut | |
| 700 | 1 | |a Ruan, Shunan |4 aut | |
| 700 | 1 | |a Liu, Wen |4 aut | |
| 700 | 1 | |a Jaki, Thomas |4 aut | |
| 700 | 1 | |a Hayden, Frederick G. |4 aut | |
| 700 | 1 | |a Horby, Peter W. |0 (orcid)0000-0002-9822-1586 |4 aut | |
| 700 | 1 | |a Cao, Bin |4 aut | |
| 700 | 1 | |a Wang, Chen |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d BioMed Central, 2000 |g 21(2020), 1 vom: 24. Mai |h Online-Ressource |w (DE-627)326173552 |w (DE-600)2040523-6 |w (DE-576)107014556 |x 1468-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:1 |g day:24 |g month:05 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13063-020-04352-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 936 | b | k | |a 44.00 |j Medizin: Allgemeines |j Medizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 1 |b 24 |c 05 | ||